Search results
26 sie 2021 · As a result, the presence of malignant ascites in advanced-stage ovarian cancer patients is associated with a poor prognosis, warranting the development of more effective treatments for the palliation of malignant ascites.
The management of malignant ascites in ovarian cancer consists of both limiting the development of peritoneal fluid accumulation and addressing its outflow. As therapies for recurrent disease rarely lead to a cure, the therapeutic intent should focus on improving QOL.
8 maj 2020 · The most important factor that influences patient prognosis in ovarian cancer is the resectability of the primary tumour and metastatic deposits—survival is optimal in cases where the...
7 lip 2020 · The most important factor that influences patient prognosis in ovarian cancer is the resectability of the primary tumour and metastatic deposits—survival is optimal in cases where the cancer is optimally debulked. 18–20 Ascites has been shown to increase the chance of suboptimal cytoreduction and is significantly associated with shorter ...
26 sie 2021 · Despite decades of evidence showing that the accumulation of peritoneal fluid portends the poorest outcomes for cancer patients, the role of malignant ascites in promoting metastasis and therapy resistance remains poorly understood. This review summarizes the current understanding of malignant ascites, with a focus on ovarian cancer.
21 lut 2013 · One study has suggested that ascites at presentation is an independent prognostic factor for time to relapse 6 and, overall, more than one-third of women with ovarian cancer develop ascites...
25 wrz 2013 · More than one third of ovarian cancer patients present with ascites at diagnosis, and almost all have ascites at recurrence. The presence of ascites correlates with the peritoneal spread of ovarian cancer and is associated with poor disease prognosis.
